| ID | 1115 | |
| PMID | 19709343 | |
| Year | 2009 | |
| Sequence | FLGGLIKIVPAMICA VTKKC | |
| Name | Ranalexin | |
| Length | 20 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Linear | |
| Chirality | L | |
| Chemical Modification | None | |
| Origin of Peptide | North American bullfrog, Rana catesbeiana | |
| Nature of Peptide/Cargo | Antimicrobial | |
| Mechanism | Ranalexinis is bactericidal in nature .The cationic loop and hydrophobic tail shared by Ranalexin and polymyxin could represent a fundamental membrane-permeabilizing peptide motif more widely utilized in nature | |
| Cargo Sequence/Structure | None | |
| Name of cargo | Not applicable | |
| Assay | Franz diffusion cell | |
| Enhancer | None | |
| Properties of enhancer | Not applicable | |
| Concentration | 10 µl MRSA252 suspension (1·108 CFU ml-1) which was allowed to dry at 25°C; 30 min, 50µl of a treatment solution made up in PBS (100 mg l-1) ranalexin | |
| Incubation time | 30 minutes | |
| Tissue permeability (value with units) | Ranalexin (100 mg l-1) reduced viable MRSA252 by 0.13 ± 0.06 log10 CFU | |
| Tissue Sample | Abdominal skin from a 38-year-old white female donor | |
| Ex vivo/In vivo/In vitro | ex vivo | |
| STRUCTURE |
| |
| SMILES | N[C@@H](Cc1ccccc1)C(=O)N[C@@H] (CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O) N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCC[NH3])C(=O) N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O) N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC) C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H] (CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O) N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCC[NH3]) C(=O)N[C@@H](CCCC[NH3])C(=O)N[C@@H](CS)C=O | |